Peter Dudek
InvestorPresident and Managing Partner at MRL Ventures Fund · Board director at Ambagon Therapeutics · Board director at Xilio Therapeutics
Cambridge, Massachusetts
About
Ph.D. and president and managing partner of MRL Ventures Fund, describing the fund as an institutional venture partner taking active board or observer roles.
Contact· published on Peter's own website
Board director at Ambagon Therapeutics
Intro paths
→
In turn, Peter can intro founders to Ambagon Therapeutics's investors below.
Ambagon Therapeutics's investors · 7
Co-founders at Ambagon Therapeutics
CO
Christian OttmannExecutive Officer
Board director at Xilio Therapeutics
Intro paths
→
In turn, Peter can intro founders to Xilio Therapeutics's investors below.
Xilio Therapeutics's investors · 11
Atlas VentureCambridge · $500K – $1M checks · since 2021Bain Capital Life SciencesBoston · since 2021Bay City CapitalSan Rafael · $5M – $10M checksF-Prime CapitalCambridge · $3M – $10M checks · since 2021M VenturesLos Angeles · $10.8M checksMRL Ventures FundCambridge · $25M checksRA CapitalBostonRiverVest Venture PartnersSt. Louis · $500K – $3M checksRock Springs CapitalBaltimoreSolasta VenturesBostonSV Health InvestorsBoston · $1M – $20M checks
Co-founders at Xilio Therapeutics
RR
Rene RussoExecutive Officer, Director
Experience
- MerckPresident & Managing Partner, MRL Ventures Fundcurrent2021 — presentBoston, Massachusetts, United States
- MerckPartner, MRL Ventures Fund2018 — 2021Boston
- Myoventive, Inc.Board Directorcurrent2025 — presentSan Francisco Bay Area
- InsamoBoard Observercurrent2024 — present
- InduProBoard Directorcurrent2022 — present
- Photys TherapeuticsBoard Observercurrent2021 — present
- Mozart Therapeutics, IncBoard Directorcurrent2020 — present
- Aktis OncologyBoard Observer2024 — 2026Boston
- Tallac TherapeuticsBoard Director2021 — 2025
- Therini Bio, Inc.Board Director2024 — 2025San Francisco
- Ambagon TherapeuticsBoard Director2020 — 2024
- Caraway Therapeutics, Inc.Board Director2021 — 2023
- Carisma TherapeuticsBoard Observer2018 — 2023
- LifeMine TherapeuticsBoard Observer2021 — 2023
- HotSpot Therapeutics, Inc.Board Observer2020 — 2022
- Xilio Therapeutics, Inc.Board Observer2021
- Xilio Therapeutics, Inc.Board Director2019 — 2021
- Imago BioSciences, Inc.Board Observer2018 — 2021
- Kymera TherapeuticsBoard Observer2018 — 2020
- Wellington PartnersPrincipal2016 — 2018London / Munich
- Entrepreneurs FundAssociate2011 — 2016London
- Novartis Venture FundIntern Analyst / Consultant2009 — 2011
- Private Biopharmaceutical CompaniesConsultant2009 — 2011
- University of OxfordPost Doctoral Fellow2007 — 2009
- University of GenevaDoctoral Student2000 — 2006
- BC Centre for Disease ControlResearch Assistant2000
Skills & more
Biotechnology15Biopharmaceuticals3Medical Devices5Life Sciences8Diagnostics1Healthcare1Venture Capital17Entrepreneurship11Valuation4Competitive Intelligence2Market Analysis2Due Diligence3
+10 more
LifesciencesMolecular BiologyMolecular CloningBiochemistryGeneticsCommercializationData AnalysisNeuroscienceR&DResearchLanguages English · French · Polish
From Peter's professional profile.
Colleagues at MRL Ventures Fund
Dr. Amit N. Thakker
Africa Healthcare Adviser at Asia Africa Investment & Consulting (AAIC)
Jason Ruth
Partner at MRL Ventures Fund
Karin Kleinhans
Partner at MRL Ventures Fund
Melissa Danforth
General Counsel, Life Sciences at Bain Capital Life Sciences
Olga Danilchanka
Partner at MRL Ventures Fund
Priya Agrawal
MSD at i3 — Investing in Innovation Africa
Tao Fang
Senior Associate at MRL Ventures Fund
Frequently asked questions
- Who is Peter Dudek?
- Ph.D. and president and managing partner of MRL Ventures Fund, describing the fund as an institutional venture partner taking active board or observer roles.
- Where does Peter Dudek work?
- Peter Dudek is President and Managing Partner at MRL Ventures Fund and Board director at Ambagon Therapeutics and Board director at Xilio Therapeutics.
- Where did Peter Dudek go to school?
- Peter Dudek studied at University of Oxford (Technology Spin-out Management Programme); Saïd Business School, University of Oxford (Building a Business, Medical Innovation); University of Geneva (Doctor of Philosophy, Cell Biology).
Same school
Also attended Saïd Business School, University of Oxford253
Manuk HergnyanCo-Founder & Managing Partner at Granatus VenturesMike MoradiGeneral Partner at Cortado VenturesConnor WhitingFinance Associate at Giant Ventures Global LlpBrendan BakerPartner at Rackhouse Venture Management LpMorgan GerlakPartner at TCVThomasGeneral Partner at Acadian Ventures Management, Llc
.png)
+ 247 more
Also attended University of Geneva50
Massimo PrelzInvestor at DN CapitalChristoph FreiPartner, Head of Energy at Emerald Technology Ventures AgErich SieberFounding General Partner at PeakBridge VCDavid MarcusInvestor at FELIX CAPITALMichelle PiontekImpact & ESG Associate at AENUPatrik BrudererCFO at CV Labs
+ 44 more
Also attended The University of British Columbia250
Joan MirallesHead of Administration & Valuation at Inveready Technology Investment GroupZack GrimmerInvestor at IVP (Institutional Venture Partners)Carolina BrochadoInvestor at EQT VenturesRares CrisanInvestor at Notable CapitalMarianne WuVenture Partner at Congruent VenturesBrendan BakerPartner at Rackhouse Venture Management Lp
+ 244 more
Also attended Capilano University6
Daniel DuboisInvestor at Side Door VenturesAki SiebelinkOperations Team at Autotech VenturesSarah GowePlatform Operations Manager at Forum VenturesMichelle PavlikVice President, Communications at ForesightSamantha BradleyOperations Coordinator at Raven CapitalRichard EgliSpecial Advisor & Board Member at Alacrity Canada
